Results 281 to 290 of about 2,934,766 (329)

RETRACTION: HDAC‐Inhibitor (S)‐8 Disrupts HDAC6‐PP1 Complex Prompting A375 Melanoma Cell Growth Arrest and Apoptosis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
RETRACTION: M. Balliu, L. Guandalini, M.N. Romanelli, M. D'Amico and F. Paoletti, “HDAC‐Inhibitor (S)‐8 Disrupts HDAC6‐PP1 Complex Prompting A375 Melanoma Cell Growth Arrest and Apoptosis,” Journal of Cellular and Molecular Medicine 19, no. 1 (2015): 143–154, https://doi.org/10.1111/jcmm.12345. The above article, published online on 06 November 2014 in
wiley   +1 more source

Current HDAC Inhibitors in Clinical Trials.

CHIMIA, 2022
Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression.
Elisabetta Di Bello, Beatrice Noce, R. Fioravanti, A. Mai   +3 more
semanticscholar   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

NO-HDAC dual inhibitors

European Journal of Medicinal Chemistry, 2022
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Negar, Omidkhah, Razieh, Ghodsi
openaire   +2 more sources

Thirty years of HDAC inhibitors: 2020 hindsight.

Journal of Medicinal Chemistry, 2020
It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical ...
Terence C. S. Ho, A. Chan, Arasu Ganesan
semanticscholar   +1 more source

Multi-targeted HDAC inhibitors as Anticancer Agents: Current Status and Future Prospective.

Current Medicinal Chemistry, 2022
Multi-targeted agents can interact with multiple targets sequentially, resulting in synergistic and more effective therapies for several complicated disorders, including cancer, even with relatively modest activity.
H. Rajak, V. Patel, E. Shirbhate, Priya Tiwari, Rakesh Kore, R. Veerasamy, A. Mishra   +6 more
semanticscholar   +1 more source

Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

Expert Opinion on Therapeutic Patents, 2020
Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.
Chunlong Zhao, Hang Dong, Qifu Xu, Yingjie Zhang   +3 more
semanticscholar   +1 more source

HDAC Inhibitors

2016
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha, Mina E, Bekheet, Semira, Sheikh, Nicholas B, La Thangue   +3 more
openaire   +2 more sources

Inside HDACs with more selective HDAC inhibitors

European Journal of Medicinal Chemistry, 2016
Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compounds approved by the Food and Drug Administration. During the last five years, several groups have made continuous efforts to improve this class of compounds, designing more selective compounds or compounds with multiple ...
Roche, Joëlle, Bertrand, Philippe
openaire   +2 more sources